Drospirenone-13C3 is intended for use as an internal standard for the quantification of drospirenone by GC- or LC-MS. Drospirenone is a synthetic progestogen.1 In vivo, drospirenone inhibits spontaneous ovulation in rats (ID50s = 0.3-1.0 mg/day) when administered orally or subcutaneously.2 Drospirenone (0.5 mg/animal) administered six times per day maintains pregnancy in ovariectomized pregnant rats. It reduces serum testosterone and luteinizing hormone (LH) in cynomolgus monkeys in a dose-dependent manner. Drospirenone (10 mg/animal per day) also inhibits testosterone-induced growth of the seminal vesicles and prostate in castrated rats. Formulations containing drospirenone have been used as oral contraceptives.3
1.Pollow, K., Juchem, M., Elger, W., et al.Dihydrospirorenone (ZK30595): A novel synthetic progestagen - characterization of binding to different receptor proteinsContraception46(6)561-574(1992) 2.Muhn, P., Fuhrmann, U., Fritzemeier, K.-H., et al.Drospirenone: A novel progestogen with antimineralocorticoid and antiandrogenic activityAnn. N. Y. Acad. Sci.761(1)311-335(1995) 3.Apter, D., Zimmerman, Y., Beekman, L., et al.Bleeding pattern and cycle control with estetrol-containing combined oral contraceptives: Results from a phase II, randomised, dose-finding study (FIESTA)Contraception94(4)366-373(2016)